{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:05:04Z","timestamp":1793361904838,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"Objective<\/jats:title>To compare oliceridine and sufentanil in patient-controlled intravenous analgesia (PCIA) for reducing postoperative nausea and vomiting (PONV) in thoracoscopic surgery patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>A prospective, double-blind, randomized controlled trial enrolled 130 patients at the Affiliated Hospital of Xuzhou Medical University from December 2024 to February 2025. Patients were randomly assigned to oliceridine (Group O, n = 65) or sufentanil (Group S, n = 65) PCIA groups. General anesthesia combined with nerve block anesthesia was used intraoperatively, followed by PCIA post-surgery. The primary outcome was PONV incidence within 48\u00a0h. Secondary outcomes included nausea and vomiting scores, pain scores, rescue analgesia and antiemetic use, recovery indicators, and adverse reactions.<\/jats:p><\/jats:sec>Results<\/jats:title>Baseline and intraoperative characteristics were similar between groups. The primary outcome (48-h PONV incidence) was significantly lower in Group O (32.3% [21\/65]) than Group S (50.8% [33\/65]; P = 0.033; OR = 0.46, 95% CI [0.23\u20130.94]), especially within 24\u00a0h postoperatively. Moderate-to-severe PONV was also less frequent in Group O (18.5% vs. 38.5%, P = 0.012; OR = 0.36, 95% CI [0.16\u20130.81]). Early postoperative pain scores were similar, but Group S had higher Visual Analogue Scale (VAS) scores after 12\u00a0h (P &lt; 0.05), though the absolute differences were small (e.g., median resting VAS of 0 vs. 1\u00a0at 48\u00a0h). Rescue analgesic demand and PCIA use showed no significant difference. Group O had significantly higher Quality of Recovery-15 (QoR-15) scores (median difference at 24\u00a0h: 5.0 [95% CI 1.2\u20138.8]; P &lt; 0.05) and significantly lower Athens Insomnia Scale scores (median difference at 24\u00a0h: 1.0 [95% CI -2.3 to \u22120.5]; P &lt; 0.05) compared to Group S. Adverse reaction rates, including dizziness, nightmares, hallucinations, respiratory depression, dry mouth, allergy, and bradycardia, were similar between groups.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>In high-PONV-risk thoracoscopic surgery, oliceridine-based PCIA significantly reduced PONV incidence compared to sufentanil (32.3% vs. 50.8%, P = 0.033), while also demonstrating superior recovery quality (QoR-15) and sleep outcomes (AIS). This establishes oliceridine as a procedure-specific analgesic option for enhancing recovery beyond conventional opioid-sparing effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1576154","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:32:23Z","timestamp":1758864743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of oliceridine and sufentanil in patient - controlled intravenous analgesia for post - thoracoscopic nausea and vomiting: a prospective, double - blind, randomized controlled trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuxiang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0257279","DOI":"10.1371\/journal.pone.0257279","article-title":"Opioid-free anesthesia compared to opioid anesthesia for lung cancer patients undergoing video-assisted thoracoscopic surgery: a randomized controlled study","volume":"16","author":"An","year":"2021","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/00000542-199909000-00022","article-title":"A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers","volume":"91","author":"Apfel","year":"1999","journal-title":"Anesthesiology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/bja\/aes276","article-title":"Evidence-based analysis of risk factors for postoperative nausea and vomiting","volume":"109","author":"Apfel","year":"2012","journal-title":"Br. J. Anaesth."},{"key":"B4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1213\/01.ANE.0000068822.10113.9E","article-title":"Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged","volume":"97","author":"Apfelbaum","year":"2003","journal-title":"Anesth. Analg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40122-020-00216-x","article-title":"Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials","volume":"10","author":"Beard","year":"2021","journal-title":"Pain Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.2147\/JPR.S217563","article-title":"ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), A G-Protein selective agonist at the \u00b5-Opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy","volume":"12","author":"Bergese","year":"2019","journal-title":"J. Pain Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e230041","DOI":"10.57264\/cer-2023-0041","article-title":"Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods","volume":"13","author":"Biskupiak","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/AJP.0000000000000792","article-title":"Enhanced recovery after surgery (ERAS): a perspective review of postoperative pain management under eras pathways and its role on opioid crisis in the United States","volume":"36","author":"Echeverria-Villalobos","year":"2020","journal-title":"Clin. J. Pain"},{"key":"B10","unstructured":"FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings\n \n \n 2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/medicina54020020","article-title":"Role of multimodal analgesia in the evolving enhanced recovery after surgery pathways","volume":"54","author":"Gelman","year":"2018","journal-title":"Med. Kaunas."},{"key":"B12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/01.aco.0000247340.61815.38","article-title":"Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting","volume":"19","author":"Ho","year":"2006","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s40265-020-01414-9","article-title":"Oliceridine: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/cpdd.750","article-title":"The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine","volume":"9","author":"Nafziger","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.2147\/DDDT.S461416","article-title":"Pharmacokinetics and safety of oliceridine fumarate injection in Chinese patients with chronic non-cancer pain: a phase I, single-ascending-dose, open-label clinical trial","volume":"18","author":"Ni","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/17512433.2023.2213889","article-title":"Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Niu","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijsu.2015.01.024","article-title":"Post-operative nausea and vomiting: update on predicting the probability and ways to minimize its occurrence, with focus on ambulatory surgery","volume":"15","author":"\u00d6brink","year":"2015","journal-title":"Int. J. Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/ph14111091","article-title":"Opioid analgesia and opioid-induced adverse effects: a review","volume":"14","author":"Paul","year":"2021","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamasurg.2018.1039","article-title":"Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system","volume":"153","author":"Shafi","year":"2018","journal-title":"JAMA Surg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-Opioid receptor, for management of moderate to severe acute pain following abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"115417","DOI":"10.1016\/j.bcp.2023.115417","article-title":"Immunosuppression by opioids: mechanisms of action on innate and adaptive immunity","volume":"209","author":"Sun","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/JPR.S278279","article-title":"Oliceridine: a novel drug for the management of moderate to severe acute pain - a review of current evidence","volume":"14","author":"Tan","year":"","journal-title":"J. Pain Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14740338.2021.1965989","article-title":"Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain","volume":"20","author":"Tan","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"J. Pain Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/jocn.13789","article-title":"Postoperative pain experiences in Chinese adult patients after thoracotomy and video-assisted thoracic surgery","volume":"26","author":"Wang","year":"2017","journal-title":"J. Clin. Nurs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e13241","DOI":"10.1016\/j.heliyon.2023.e13241","article-title":"Sufentanil combined with nalmefene reduce the adverse events in recovery period of patients undergoing uvulopalatopharyngoplasty - a randomized controlled trial","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1576154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:32:25Z","timestamp":1758864745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1576154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1576154"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1576154","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1576154"}}